IP Library Granted Patent US 8,784,805
Granted Patent B2
US 8,784,805 · App. 12/919,091 · Granted Jul 22, 2014

Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases

Inventor: Rudi Brands (Bunnik, NL)
Assignee: Alloksys Life Sciences B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,805
App. No.
12/919,091
Granted
Jul 22, 2014
Kind
B2
Abstract

The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment the present invention relates to methods for the prophylaxis of mammals, and especially human mammals, at risk of inflammatory diseases such as mammals suffering from conditions such as surgery, digestive tract diseases, respiratory diseases, skin diseases, burn wounds, smoke inhalation, intoxication, severe blood loss, food poisoning, chemotherapy, radiation therapy, severe trauma or liver diseases, immunocompromised conditions. For this, the present invention provides use of an ectophosphatase for the preparation of a medicament for the prophylaxis of a mammal at risk of inflammatory diseases.

Claims (8)

1. A prophylactic method for reducing the risk of developing an inflammatory disease comprising intravenously administering an ectophosphatase to a mammal, wherein said ectophosphatase is administered in an amount effective to result in induction of endogenous ectophosphatase levels.

2. The method according to claim 1 , wherein said ectophosphatase is selected from the group consisting of alkaline phosphatase, nucleotidases, and apyrases.

3. The method according to claim 2 , wherein the ectophosphatase is selected from the group consisting of CD39, CD73, and ATP-ADPase.

4. The method according to claim 1 , wherein said method further comprises preventing an increase in levels of inflammatory markers in the mammal.

5. The method according to claim 1 , wherein said risk of developing said inflammatory disease results from a condition in which inflammatory markers are increased.

6. The method according to claim 5 , wherein said condition is selected from the group consisting of surgery, digestive tract diseases, respiratory diseases, skin diseases, burn wounds, smoke inhalation, intoxication, severe blood loss, food poisoning, chemotherapy, radiation therapy, severe trauma liver diseases, and immuno compromised conditions.

7. The method according to claim 1 , wherein said mammal is a human mammal.

8. The method of claim 1 , wherein the induction of endogenous ectophosphatase levels is provided by administration of a bolus of exogenous ectophosphatase followed by supplemental continuous administration of ectophosphatase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2010
From: BRANDS, RUDI
To: ALLOKSYS LIFE SCIENCES B.V.
Reel/Frame 025390/0605 →
Priority Claims (1)
WO PCT/EP2008/001767 · Feb 29, 2008 · international
Continuity (1)
Related Publication 20110052560A1 · Mar 3, 2011